Tech Company Financing Transactions
DiogenX Funding Round
AdBio Partners, Boehringer Ingelheim Venture Fund and Eli Lilly and Company joined a $30 million Series A funding round for DiogenX. The round was recorded on 5/10/2023.
Transaction Overview
Company Name
Announced On
5/10/2023
Transaction Type
Venture Equity
Amount
$29,996,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance the lead drug candidate towards clinical development in patients with type 1 diabetes (T1D).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
180 avenue du Prado
Marseille, 13008
FR
Marseille, 13008
FR
Phone
Undisclosed
Website
Email Address
Overview
DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes. Founded in 2020 based on the research of leading type 1 (T1D) diabetes scientist Patrick Collombat on pancreatic beta cell regeneration, DiogenX is developing first-in-class recombinant proteins designed for the treatment of T1D.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Charles
Co-Founder
Patrick Collombat
Co-Founder
Jean Tranié
Browse more venture capital transactions:
Prev: 5/10/2023: Mycocycle venture capital transaction
Next: 5/10/2023: Soptle venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs